Among the newer antiseizure medications, lacosamide (LCM) has been increasingly used for acute seizures and status epilepticus in intensive care unit (ICU). We reviewed retrospectively weight-based dosing of IV LCM in patients admitted to ICU with acute seizures and status epilepticus. We have analyzed 354/382 patient treated with IV LCM in ICU during the years 2013-2016. Data collected were age, total body weight, body mass index (BMI), loading dose, post-IV infusion LCM blood level, duration of infusion, blood pressure, heart rate, oxygen saturation, mean arterial pressures, and documented initiation of pressor agents during or within in 30 min of infusion. Larger doses >8 mg/kg of IV LCM that can be safely administered in ICU patients produce effective plasma levels of 15-20 μg/ml with relatively constant volume of distribution.

中文翻译：

---

ICU中基于体重的拉考沙胺静脉负荷剂量的安全性、耐受性和药代动力学

在较新的抗癫痫药物中，拉考沙胺 (LCM) 越来越多地用于重症监护病房 (ICU) 的急性癫痫发作和癫痫持续状态。我们回顾性地回顾了因急性癫痫发作和癫痫持续状态而入住 ICU 的患者中基于体重的 IV LCM 剂量。我们分析了 2013-2016 年间在 ICU 接受 IV LCM 治疗的 354/382 名患者。收集的数据包括年龄、总体重、体重指数 (BMI)、负荷剂量、IV 输注后 LCM 血液水平、输注持续时间、血压、心率、氧饱和度、平均动脉压和记录的升压剂启动输注期间或输注 30 分钟内。可以在 ICU 患者中安全使用的更大剂量的大于 8 mg/kg 的 IV LCM 产生 15-20 μg/ml 的有效血浆水平，分布容积相对恒定。